A
-
Abd El-Gaid, Salwa
Value of F-18 FDG PET/CT Compared to Conventional Imaging in changing management of Patients with Differentiated Thyroid Cancer before radioactive iodine ablation. [Volume 25, Issue 2, 2022, Pages 63-77]
-
Abdelmoteleb, Asmaa Magdy
ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience) [Volume 25, Issue 2, 2022, Pages 45-62]
-
Abougabal, Mahasen Amin
The correlation between 18F FDG PET CT metabolic parameters and pathological prognostic factors in early breast cancer patients [Volume 25, Issue 2, 2022, Pages 30-44]
-
Ahmad, Yasser Mohamed
ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience) [Volume 25, Issue 2, 2022, Pages 45-62]
B
-
Badawy, Ahmed Mohamed
Role of FDG/CT Scan Quantitative Analysis in Assessment of both Hodgkin and Non-Hodgkin lymphoma [Volume 25, Issue 2, 2022, Pages 15-29]
-
Badawy, Ahmed Mohamed
ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience) [Volume 25, Issue 2, 2022, Pages 45-62]
E
-
Elantably, Ismail Mohamed
Value of F-18 FDG PET/CT Compared to Conventional Imaging in changing management of Patients with Differentiated Thyroid Cancer before radioactive iodine ablation. [Volume 25, Issue 2, 2022, Pages 63-77]
-
El-rasad, Shimaa
Role of FDG/CT Scan Quantitative Analysis in Assessment of both Hodgkin and Non-Hodgkin lymphoma [Volume 25, Issue 2, 2022, Pages 15-29]
-
Elsaban, Khalid Reda
Role of FDG/CT Scan Quantitative Analysis in Assessment of both Hodgkin and Non-Hodgkin lymphoma [Volume 25, Issue 2, 2022, Pages 15-29]
-
Elsayed, Nahla Dessoki
Role of FDG/CT Scan Quantitative Analysis in Assessment of both Hodgkin and Non-Hodgkin lymphoma [Volume 25, Issue 2, 2022, Pages 15-29]
H
-
Hassan, Marwa Abd Allah
Role of FDG/CT Scan Quantitative Analysis in Assessment of both Hodgkin and Non-Hodgkin lymphoma [Volume 25, Issue 2, 2022, Pages 15-29]
-
Husseini, Maha Abd Elkareem
Does blood glucose level have influence on 18F-FDG metabolic indices in normal and neoplastic tissues [Volume 25, Issue 2, 2022, Pages 8-14]
-
Husseini, Maha Abd Elkareem
The correlation between 18F FDG PET CT metabolic parameters and pathological prognostic factors in early breast cancer patients [Volume 25, Issue 2, 2022, Pages 30-44]
I
-
Ibrahim, Dalia
Value of F-18 FDG PET/CT Compared to Conventional Imaging in changing management of Patients with Differentiated Thyroid Cancer before radioactive iodine ablation. [Volume 25, Issue 2, 2022, Pages 63-77]
-
Ibrahim, Hassan Salah
Estimation of The Patient’s Specific Effective Dose for The Total Body F18- FDG PET/CT Scan, A Single Centre Experience [Volume 25, Issue 2, 2022, Pages 78-88]
K
-
Kandil, Ahmed
ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience) [Volume 25, Issue 2, 2022, Pages 45-62]
M
-
Maamoun, Marwa Mohammad
Does blood glucose level have influence on 18F-FDG metabolic indices in normal and neoplastic tissues [Volume 25, Issue 2, 2022, Pages 8-14]
-
Mohamed, Ahmed Abdel Hafeez
The correlation between 18F FDG PET CT metabolic parameters and pathological prognostic factors in early breast cancer patients [Volume 25, Issue 2, 2022, Pages 30-44]
N
-
Nasr, Nourhan Kotb
The correlation between 18F FDG PET CT metabolic parameters and pathological prognostic factors in early breast cancer patients [Volume 25, Issue 2, 2022, Pages 30-44]
S
-
Saad Ahmed, Ibrahim Elsayed
Availability and Affordability Of PET Tracers, The Challenges and Opportunities in Developing Countries [Volume 25, Issue 2, 2022, Pages 1-7]
-
Saad Ahmed, Ibrahim Elsayed
Estimation of The Patient’s Specific Effective Dose for The Total Body F18- FDG PET/CT Scan, A Single Centre Experience [Volume 25, Issue 2, 2022, Pages 78-88]
T
-
Tawakol, Ahmed
ASSESSMENT OF TREATMENT RESPONSE TO 131I THERAPY FOR PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA IN THE PAST THREE YEARS (Single Institutional Experience) [Volume 25, Issue 2, 2022, Pages 45-62]
Your query does not match with any item